Biocon to form JV with Neopharma in Dubai

Bangalore, July 30: Indian Biotechnology major, Biocon Limited and Abu Dhabi based pharmaceutical manufacturer Neopharma today announced setting up of a joint Venture Neobiocon to be established at the Dubai Biotechnology and Research Park (Dubiotech).

Biocon, in a release here, said that the JV would provide affordable life saving drugs to the people of the United Arab Emirates. Neobiocon was a pioneering initiative that heralds the region's first foray to develop and market life saving biopharmaceutical niche products in key therapeutic areas such as oncology, diabetes, auto-immune disorders, cardiology, anti-obesity drugs and new generation immunosuppressant drugs, it said.

Neobiocon would take initiatives to educate people on the debilitating effects of lifestyle diseases by rolling out educational campaigns through physician workshops. There would be a dual approach of local development coupled with educational programmes/workshops that would benefit the local population.

Dubiotech provided infrastructure to various companies to set up their own establishments apart from offering ready made offices for R&D, pilot production and storage facilities. Dubiotech helped bridge research, education and industry through national and international collaboration.

Commenting on the new venture BIOCON Chairman and Managing Director Kiran Mazumdar-Shaw said ''the establishment of Neobiocon takes our recently announced JV with Neopharma a step further. This in fact is a continuation of our tie-up. We are delighted to be able to provide the advantage of Biocon's proprietary biotech and other related biopharmaceutical pipeline products to the people in this region. Our long term vision is to ensure that the country is self-sufficient in terms of biopharmaceutical products''.

UNI